243 related articles for article (PubMed ID: 18791333)
1. Legal assessment of current situation on orphan patients in Lithuania.
Spokiene I
Medicina (Kaunas); 2008; 44(8):571-6. PubMed ID: 18791333
[TBL] [Abstract][Full Text] [Related]
2. Drugs for rare diseases: mixed assessment in Europe.
Prescrire Int; 2007 Feb; 16(87):36-42. PubMed ID: 17323539
[TBL] [Abstract][Full Text] [Related]
3. A cross-national comparative study of orphan drug policies in the United States, the European Union, and Japan: towards a made-in-China orphan drug policy.
Liu BC; He L; He G; He Y
J Public Health Policy; 2010 Dec; 31(4):407-20; discussion 420-1. PubMed ID: 21119648
[TBL] [Abstract][Full Text] [Related]
4. EU orphan regulation--ten years of application.
Michaux G
Food Drug Law J; 2010; 65(4):639-69, i-ii. PubMed ID: 24479246
[TBL] [Abstract][Full Text] [Related]
5. The European Union Policy in the Field of Rare Diseases.
Moliner AM; Waligora J
Adv Exp Med Biol; 2017; 1031():561-587. PubMed ID: 29214592
[TBL] [Abstract][Full Text] [Related]
6. [Orphan drugs: availability, reliability and reimbursement].
Kreeftmeijer-Vegter AR; van Veldhuizen CK; de Vries PJ
Ned Tijdschr Geneeskd; 2012; 156(17):A4252. PubMed ID: 22531041
[TBL] [Abstract][Full Text] [Related]
7. [European incentives for orphan medicinal products].
Enzmann H; Lütz J
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2008 May; 51(5):500-8. PubMed ID: 18696141
[TBL] [Abstract][Full Text] [Related]
8. Creating a European Union framework for actions in the field of rare diseases.
Moliner AM
Adv Exp Med Biol; 2010; 686():457-73. PubMed ID: 20824460
[TBL] [Abstract][Full Text] [Related]
9. Navigating through orphan medicinal product regulations in EU and US--similarities and differences.
Tiwari J
Regul Toxicol Pharmacol; 2015 Feb; 71(1):63-7. PubMed ID: 25497996
[TBL] [Abstract][Full Text] [Related]
10. European regulation on orphan medicinal products: 10 years of experience and future perspectives.
; Westermark K; Holm BB; Söderholm M; Llinares-Garcia J; Rivière F; Aarum S; Butlen-Ducuing F; Tsigkos S; Wilk-Kachlicka A; N'Diamoi C; Borvendég J; Lyons D; Sepodes B; Bloechl-Daum B; Lhoir A; Todorova M; Kkolos I; Kubáčková K; Bosch-Traberg H; Tillmann V; Saano V; Héron E; Elbers R; Siouti M; Eggenhofer J; Salmon P; Clementi M; Krieviņš D; Matulevičiene A; Metz H; Vincenti AC; Voordouw A; Dembowska-Bagińska B; Nunes AC; Saleh FM; Foltánová T; Možina M; Torrent i Farnell J; Beerman B; Mariz S; Evers MP; Greene L; Thorsteinsson S; Gramstad L; Mavris M; Bignami F; Lorence A; Belorgey C
Nat Rev Drug Discov; 2011 May; 10(5):341-9. PubMed ID: 21532564
[TBL] [Abstract][Full Text] [Related]
11. Orphan medicinal products in Europe and United States to cover needs of patients with rare diseases: an increased common effort is to be foreseen.
Giannuzzi V; Conte R; Landi A; Ottomano SA; Bonifazi D; Baiardi P; Bonifazi F; Ceci A
Orphanet J Rare Dis; 2017 Apr; 12(1):64. PubMed ID: 28372595
[TBL] [Abstract][Full Text] [Related]
12. No difference in between-country variability in use of newly approved orphan and non- orphan medicinal products--a pilot study.
Stolk P; Heemstra HE; Leufkens HG; Bloechl-Daum B; Heerdink ER
Orphanet J Rare Dis; 2009 Dec; 4():27. PubMed ID: 20003427
[TBL] [Abstract][Full Text] [Related]
13. European Medicines Agency support mechanisms fostering orphan drug development.
Butlen-Ducuing F; Rivière F; Aarum S; Llinares-Garcia J
Drug News Perspect; 2010; 23(1):71-81. PubMed ID: 20155221
[TBL] [Abstract][Full Text] [Related]
14. Orphan drug development across Europe: bottlenecks and opportunities.
Heemstra HE; de Vrueh RL; van Weely S; Büller HA; Leufkens HG
Drug Discov Today; 2008 Aug; 13(15-16):670-6. PubMed ID: 18583178
[TBL] [Abstract][Full Text] [Related]
15. Trends in orphan medicinal products approvals in the European Union between 2010-2022.
Bouwman L; Sepodes B; Leufkens H; Torre C
Orphanet J Rare Dis; 2024 Feb; 19(1):91. PubMed ID: 38413985
[TBL] [Abstract][Full Text] [Related]
16. The challenges of orphan drugs and orphan diseases: real and imagined.
Hudson I; Breckenridge A
Clin Pharmacol Ther; 2012 Aug; 92(2):151-3. PubMed ID: 22814659
[TBL] [Abstract][Full Text] [Related]
17. Legal instruments supporting the development of orphan medicinal products in the European Union.
Miaskowska-Daszkiewicz K
Acta Pol Pharm; 2014; 71(1):181-7. PubMed ID: 24779206
[TBL] [Abstract][Full Text] [Related]
18. Access to orphan drugs in Europe: current and future issues.
Michel M; Toumi M
Expert Rev Pharmacoecon Outcomes Res; 2012 Feb; 12(1):23-9. PubMed ID: 22280193
[TBL] [Abstract][Full Text] [Related]
19. Fighting trafficking of falsified and substandard medicinal products in Russia.
Fayzrakhmanov NF
Int J Risk Saf Med; 2015; 27 Suppl 1():S37-40. PubMed ID: 26639702
[TBL] [Abstract][Full Text] [Related]
20. [Orphan drugs: some legal, ethical and economics aspects].
Pabst JY
Rev Epidemiol Sante Publique; 2001 Sep; 49(4):387-96. PubMed ID: 11567205
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]